<DOC>
	<DOCNO>NCT00111605</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability experimental HIV vaccine . The vaccine give without IL-12 DNA adjuvant ( three escalate dos 100 , 500 , 1,500 mcg respectively ) , substance help body respond vaccine . This study also determine safety tolerability experimental HIV vaccine boost two adjuvant .</brief_summary>
	<brief_title>Study HIV Preventive Vaccine Given With Without Adjuvant HIV Uninfected Adults</brief_title>
	<detailed_description>The HIV epidemic major global health challenge , cause tremendous human suffer economic loss throughout world . The need safe , effective , affordable HIV preventive vaccine critical . This study determine safety immunogenicity experimental HIV vaccine , HIV-1 gag DNA , give without IL-12 adjuvant boost HIV-1 gag DNA without IL-12 DNA adjuvant . This study comprise two part ( Parts A B ) . Part A last 9 month Part B , 15 month . Part A consist 48 participant enrol 4 group . Group 1 participant randomly assign receive gag DNA vaccine placebo . Participants Groups 2 , 3 , 4 randomly assign receive gag DNA vaccine either 100 mcg , 500 mcg , 1,500 mcg IL-12 DNA placebo . Vaccinations Groups 1 4 give intramuscularly occur study entry Months 1 3 . Part B consist 96 participant , enrol 3 group . Participants Part B receive first vaccination 2 week Part A participant receive second vaccination . Group 5 participant receive either HIV-1 gag DNA vaccine placebo . Group 6 participant receive either HIV-1 gag DNA vaccine plus IL-12 DNA placebo . Vaccinations Groups 5 6 occur study entry Months 1 , 3 , 6 , 9 . Group 7 participant receive either gag DNA vaccine plus IL-12 DNA placebo study entry Months 1 3 . Throughout study , blood urine collection occur , physical exam conduct , HIV test counseling offer , interview questionnaire complete .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>HIV uninfected Access participate HIV Vaccine Trials Unit ( HVTU ) Willing receive HIV test result Willing able comply study requirement In good general health Willing use acceptable method contraception least 21 day prior study entry last study visit . More information criterion find protocol . Hepatitis B surface antigen negative Antihepatitis C virus ( antiHCV ) antibody negative negative HCV PCR antiHCV antibody positive Weighs great 110 pound ( 50 kg ) HIV infection HIV vaccine placebos prior HIV trial Immunosuppressive medication within 168 day prior first study vaccination Blood product within 120 day prior first study vaccination Live attenuate vaccine within 30 day prior first study vaccination Medically indicate subunit kill vaccine within 14 day prior first study vaccination Pneumococcal vaccine within 14 day prior first study vaccination Allergy treatment antigen injection within 30 day prior first study vaccination Current antituberculosis ( TB ) preventive therapy treatment Clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health Any medical , psychiatric , social condition would interfere study . More information criterion find protocol . Any jobrelated responsibility would interfere study Allergies local amidetype anesthetic Serious adverse reaction vaccine , include hypersensitivity relate symptom . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Active syphilis infection . Participants fully treat syphilis 6 month prior study entry exclude . Moderate severe asthma . More information criterion find protocol . Type 1 type 2 diabetes mellitus . Participants history isolate gestational diabetes exclude . Thyroid disease surgical removal thyroid require medication 12 month prior study entry Accumulation fluid blood vessel ( angioedema ) within 3 year prior study entry , episodes require medication 2 year prior study entry Hypertension well control medication OR blood pressure 150/100 high study entry Body mass index ( BMI ) 40 great OR BMI 35 great , certain criterion meet . More information criterion find protocol . Bleeding disorder Cancer . Participants surgically remove cancer , opinion investigator , unlikely recur exclude . Absence spleen Plans become pregnant study Pregnancy breastfeed Exclusion Criterion Participants Part B : Allergies yeastderived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Vaccines</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>